3‑in‑1 Automated Platform Speeds Up CAR‑T Manufacturing in Just 7 Days

Published by Cytotherapy via LinkedIn

A new paper describes a fully integrated platform that automates three core CAR‑T manufacturing steps: activation, viral transduction, and expansion; under serum-free conditions using the Quantum Cell Expansion System. Developed by teams from Terumo Blood and Cell Technologies and Eureka Biotech, the system reduces cycle time to just 7–8 days and produces consistent 12-billion-cell batches with high transduction efficiency and memory-like phenotypes. The GMP-compliant platform improves safety, cost, and scalability for broader CGT access.

Read the full article on Cytotherapy:

👉 A 3-in-1 integrated automated platform for rapid CAR-T cell manufacturing: activation, transduction, and expansion in a hollow-fiber system

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.